On 12 December 2017, orphan designation (EU/3/17/1951) was granted by the European Commission to Clinical Network Services (UK) Ltd, United Kingdom, for agammaglobulinaemia tyrosine kinase (also known as PRN1008) for the treatment of pemphigus.
The sponsorship was transferred to Clinical Network Services (NL) B.V., The Netherlands, in January 2019.
In August 2020, Clinical Network Services (NL) B.V.changed name to Scendea (NL) B.V.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in November 2021 on request of the Sponsor.
Agammaglobulinaemia tyrosine kinase
Treatment of pemphigus
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: